NIB Holdings Ltd (ASX: NHF) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


NIB Holdings Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $3.10 billion
P/E Ratio 19.27
Dividend Yield 3.54%
Shares Outstanding 456.73 million
Earnings per share 0.217
Dividend per share 0.28
Year To Date Return 17.59%
Earnings Yield 5.19%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

NIB Holdings Ltd (ASX: NHF)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
02 Sep 2021 $0.1400 100.00% Final 05 Oct 2021
04 Mar 2021 $0.1000 100.00% Interim 06 Apr 2021
03 Sep 2020 $0.0400 100.00% Final 06 Oct 2020
05 Mar 2020 $0.1000 100.00% Interim 07 Apr 2020
02 Sep 2019 $0.1300 100.00% Final 30 Sep 2019
28 Feb 2019 $0.1000 100.00%
06 Sep 2018 $0.1100 100.00% Final 05 Oct 2018
01 Mar 2018 $0.0900 100.00% Interim 03 Apr 2018
07 Sep 2017 $0.1050 100.00% Final 06 Oct 2017
02 Mar 2017 $0.0850 100.00% Interim 03 Apr 2017
08 Sep 2016 $0.0900 100.00% Final 07 Oct 2016
02 Mar 2016 $0.0575 100.00% Interim 01 Apr 2016
09 Sep 2015 $0.0600 100.00% 09 Oct 2015
04 Mar 2015 $0.0550 100.00% 02 Apr 2015
10 Sep 2014 $0.0900 100.00% Special Cash 03 Oct 2014
10 Sep 2014 $0.0575 100.00% Final 03 Oct 2014
05 Sep 2013 $0.0500 100.00% Final 04 Oct 2013
04 Mar 2013 $0.0500 100.00% Interim 05 Apr 2013
05 Mar 2012 $0.0425 100.00% Interim 05 Apr 2012
07 Mar 2011 $0.0400 100.00% Interim 08 Apr 2011
05 Mar 2010 $0.0200 100.00% Interim 08 Apr 2010
14 Sep 2009 $0.0440 100.00% Final 09 Oct 2009

NHF ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About NIB Holdings Ltd

NIB Holdings Limited (ASX:NHF) was originally known as Newcastle Industrial Benefits. The company was established in the Hunter region of New South Wales in 1952 to provide health insurance for workers at the BHP steelworks. Since its humble beginnings, NIB has grown to become a national and international insurer with a notable share of the Australian and New Zealand private health insurance market.

Beyond health insurance, NIB also provides life insurance as well as travel insurance to its customers across Australia and around the world. NIB is now Australia’s third largest provider of travel insurance.

According to the company’s website, NIB provides health insurance to over 1.6 million people across Australia and New Zealand as well as nearly 200,000 international students and overseas workers in Australia.

The health fund was demutualised on 19 July 2007 and, on the same day, became Australia’s first private health fund to list on the ASX. The NIB share price opened its first day of trade at 85 cents and has since gone on to reach as high as $8 in July 2019.

NHF Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Sep 2021 $6.78 $0.00 0.00% 1,101,775 $6.74 $6.82 $6.70
16 Sep 2021 $6.78 $0.04 0.59% 843,488 $6.77 $6.83 $6.71
15 Sep 2021 $6.74 $0.09 1.35% 751,938 $6.65 $6.79 $6.63
14 Sep 2021 $6.65 $0.06 0.91% 1,337,365 $6.63 $6.65 $6.51
13 Sep 2021 $6.59 $0.03 0.46% 545,555 $6.50 $6.61 $6.47
10 Sep 2021 $6.56 $-0.02 -0.30% 916,233 $6.57 $6.67 $6.48
09 Sep 2021 $6.58 $-0.18 -2.66% 763,621 $6.72 $6.73 $6.55
08 Sep 2021 $6.76 $0.02 0.30% 524,540 $6.65 $6.76 $6.57
07 Sep 2021 $6.74 $0.04 0.60% 463,173 $6.70 $6.77 $6.69
06 Sep 2021 $6.70 $0.00 0.00% 663,772 $6.67 $6.71 $6.62
03 Sep 2021 $6.70 $0.11 1.67% 358,066 $6.64 $6.72 $6.58
02 Sep 2021 $6.59 $-0.19 -2.80% 822,547 $6.60 $6.65 $6.51
01 Sep 2021 $6.78 $0.01 0.15% 387,951 $6.69 $6.78 $6.65
31 Aug 2021 $6.77 $0.03 0.45% 740,560 $6.75 $6.83 $6.68
30 Aug 2021 $6.74 $0.09 1.35% 1,100,654 $6.63 $6.78 $6.55
27 Aug 2021 $6.65 $-0.03 -0.45% 721,213 $6.60 $6.69 $6.59
26 Aug 2021 $6.68 $0.08 1.21% 1,516,395 $6.52 $6.70 $6.48
25 Aug 2021 $6.60 $0.01 0.15% 3,154,730 $6.53 $6.68 $6.39
24 Aug 2021 $6.59 $-0.51 -7.18% 4,031,810 $6.98 $6.98 $6.54
23 Aug 2021 $7.10 $-0.88 -11.03% 2,936,945 $7.58 $7.64 $7.05
20 Aug 2021 $7.98 $0.09 1.14% 741,713 $7.90 $8.05 $7.83

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 Sep 2021 Mark Fitzgibbon Sell 30 $200,845
On-market trade.
09 Sep 2021 Mark Fitzgibbon Transfer 10 $66,111
Off-market transfer. Estimated Value
08 Sep 2021 Mark Fitzgibbon Transfer 20 $134,428
Off-market transfer. Estimated Value
08 Sep 2021 Mark Fitzgibbon Sell 25 $168,301
On-market trade.
01 Sep 2021 Mark Fitzgibbon Exercise 142 $968,658
Conversion of securities. 810,814 - Performance Rights
01 Sep 2021 Mark Fitzgibbon Buy 142 $968,658
Conversion of securities.
01 Sep 2021 Mark Fitzgibbon Issued 82 $559,194
Issue of securities.
01 Sep 2021 Mark Fitzgibbon Expiry 79 $538,521
As advised by the company. 731,386 - Performance Rights
30 Aug 2021 Peter Harmer Buy 11 $74,998
On-market trade.
30 Aug 2021 Mark Fitzgibbon Sell 30 $201,000
On-market trade.
31 May 2021 Steven (Steve) Crane Sell 47 $293,027
On-market trade.
27 May 2021 Steven (Steve) Crane Sell 102 $633,200
On-market trade.
26 May 2021 David Gordon Buy 30 $184,795
On-market trade.
30 Apr 2021 Mark Fitzgibbon Sell 45 $275,062
On-market trade.
24 Feb 2021 Mark Fitzgibbon Sell 45 $252,051
On-market trade.
27 Nov 2020 Mark Fitzgibbon Issued 314 $1,627,474
Issue of securities. 953,684 - Performance Rights
25 Nov 2020 Mark Fitzgibbon Transfer 100 $500,000
Off-market transfer.
25 Nov 2020 Mark Fitzgibbon Transfer 100 $500,000
Off-market transfer.
22 Sep 2020 Mark Fitzgibbon Sell 32 $137,169
On-market trade.
21 Sep 2020 Mark Fitzgibbon Sell 24 $104,643
On-market trade.
18 Sep 2020 Mark Fitzgibbon Sell 2 $10,878
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr David L Gordon Non-Executive DirectorNon-Executive Chairman May 2020
Mr Gordon has over 20 years' experience as a director of both public and private companies and has experience in the corporate advisory and financial services sector. He is currently Chair of Accent Group Limited and Founding Principal of Lexicon Partners. He was previously a Director and Chair of Ten Network Holdings and held senior roles at Herbert Smith Freehills and boutique investment bank, Wentworth Associates.
Ms Anne Joan Loveridge Non-Executive Director Feb 2017
Ms Loveridge has over 35 years of experience in banking, wealth management, private equity and property. She has knowledge of financial and regulatory reporting, risk management controls and compliance frameworks. She also has experience as a Committee Chairperson. Formally trained as a Chartered Accountant, Anne has a of experience in financial reporting, auditing, risk, ethics and regulatory affairs following her 31 years with PwC Australia, where she retired as Partner and Deputy Chair in 2015. Through senior leadership roles in the firm, Anne also has experience and a focus on leadership, performance and culture. She was specifically involved in the creation of targets, mentoring and development programs for senior executives, as well as evaluating organisational training programs to identify areas of bias. Anne Loveridge is entitled to receive a retirement benefit from PwC as part of her retirement plan. The amount of the payment was determined at the time of retirement, based on role and tenure with the firm. The benefit is not impacted by the revenue, profits or earnings of PwC. Anne has declared her previous relationship with PwC to the nib Board and the Board is satisfied that it does not affect her independence as Non-Executive Director and does not constitute a conflict of interest. The nib Board has in place mechanisms to manage conflicts of interest where they arise. Anne is a Non-Executive Director of Platinum Asset Management (Chair of the Audit, Risk and Compliance Committee) and a Non-Executive Director of National Australia Bank Limited (Chair of the Remuneration Committee). Anne is Chair of Australian theatre company, Bell Shakespeare Limited. She is the member of the Investment Committee, Risk and Reputation Committee.
Mr Donal Paul O'Dwyer Non-Executive Director Mar 2016
Mr O'Dwyer is also a Director of nib health funds limited. Industry experience Donal has a knowledge of the health industry globally, after more than 35 years in senior executive and Non-Executive Director roles within the healthcare products and medical device sectors. He went on to gain experience in business, science, engineering, manufacturing and management. During his tenure with Baxter Healthcare, he rose through the ranks from plant manager to President of the Cardiovascular Group Europe, gaining a understanding of the inner workings of business strategy and fiscal management, from the floor of the factory through to the boardroom. He then worked for Cordis (the cardiovascular device franchise of Johnson & Johnson) - initially as European President and later, when he located to the US, he served as Worldwide President. In his role as member of the nib Risk and Reputation Committee, Donal has a interest in environmental, social and governance factors and how these performance indicators can help promote long-term financial success. Donal is a Non-Executive Director of Cochlear Ltd, Mesoblast Ltd (Chair of the Nomination and Remuneration Committee) and Fisher & Paykel Healthcare Corporation Ltd. He was director of Chair of CardieX Limited (formerly AtCor Medical Holdings Limited). He is Chair of the Investment Committee, and a member of the Risk and Reputation Committee, People Committee.
Mark Fitzgibbon Chief Executive OfficerManaging Director May 2007
Mr Fitzgibbon is a Director of nib health funds limited, as well as many other nib holdings limited's subsidiaries. He is also a member of nib holding's Nomination Committee. Industry experience Mark has held executive positions at a number of large Australian organisations, including local government councils and peak bodies. Leading nib for almost 20 years, Mark has transformed the business from a regionally based (Newcastle, NSW) private health insurer into one of Australia's fastest growing and innovative health funds. As Managing Director, Mark's strategic focus has been to grow and diversify nib's business and with that earnings by leveraging nib's capability, systems and people. Mark has previously served as CEO of both the national and NSW peak industry bodies for licensed clubs, as well as holding several General Manager positions in local government. Other commitments Mark is currently a Director of Private Healthcare Australia.
Ms Lee Ausburn Non-Executive Director Nov 2013
Ms Ausburn have more than 30 years experience in the pharmaceuticals industry, Lee has a wealth of knowledge in the global health industry. Lee have experience in retail and hospital pharmacy, as well as in academia. She had a career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President - Asia for Merck and Co Inc with responsibility for the company's operations across nine countries. At Merck and Co Inc, Lee built high performing organisations with enhanced ethical and compliance frameworks, across the Asia Pacific region. She also has marketing experience with customer centric approaches that had proven results with the region growing strongly under her leadership. Operating in a highly regulated industry, Lee also developed strong regulatory and government relations skills. She also has experience operating joint ventures, including chairing the Far East Operating Board, overseeing the successful Merck- Schering Plough Asia Pacific Joint Venture from 2003 to 2007. Lee is currently a Director of pharmaceutical wholesaling and pharmacy retail business, Australian Pharmaceutical Industries Ltd. Other business and market experience Lee was previously a member (2010-2015) and President (2015- 2017) of the Pharmacy Foundation at the University of Sydney. She's also been an industry representative on the Australian Government's Pharmaceutical Health and Rational Use of Medicines Committee (1993-1996) and the Drug Utilisation Subcommittee (1995-1997). In NSW, she was a Board member of NSW Health's Clinical Excellence Commission and the Agency for Clinical Innovation (2010-2014), established to enhance quality and safety in NSW hospitals. Lee is currently a Mentor for Women on Boards. She is Chair of the People Committee and a member of the Risk and Reputation Committee.
Mr Peter Harmer Non-Executive Director Jul 2021
Mr Harmer has over 40 years' experience in the Australian and international insurance and financial sectors, including over 30 years in a senior executive capacity. He was formerly Chief Executive Officer of Insurance Australia Group (IAG), CGU Insurance, Aon Limited UK, Aon Risk Services Australia Pacific and Aon Re Australia. Mr Harmer was also Chairman of Aon Re Australia and the London Market Reform Group and is currently a Non-Executive Director of the Commonwealth Bank of Australia.
Ms Jacqueline Chow Non-Executive Director Apr 2018
Ms Chow has more than 20 years experience working with global blue-chip consumer product multinationals in a range of executive and non-executive positions in general management, strategy, marketing as well as technology and innovation. Her early career concentrated on business analytics, brand equity and marketing. Jacqueline is currently a Non-Executive Director of Coles Group Limited. Other business and market experience Jacqueline has significant global experience driving strategic growth and innovation across customer and consumer brands for the likes of Fonterra, Campbell Arnott's and the Kellogg Company. She was previously Deputy Chair of Global Dairy Platform and a Director of Fisher & Paykel Appliances in New Zealand, Dairy Partners Americas, the Riddet Institute (Massey University NZ) and The Arnott's Foundation. In her role with McKinsey & Company RTS, she advises clients across resources, retail, financial services, telecommunications and consumer sectors on organisational change and high performance culture. Other commitments Jacqueline is a Non-Executive Director of the Australia-Israel Chamber of Commerce and a senior advisor with McKinsey & Company RTS. She is Chair of the Risk and Reputation Committee and a member of the People Committee.
Mrs Michelle McPherson Deputy Chief Executive OfficerChief Financial Officer Sep 2008
Ms Roslyn Toms Group Executive - Legal and Chief Risk OfficerCompany Secretary Apr 2013
Mr Jordan French Senior Corporate CounselJoint Company Secretary Aug 2017
Rob Hennin Chief Executive Officer - New Zealand (CEO NZ)
Brendan Mills Chief Information Officer (CIO)
Michelle McPherson Deputy Chief Executive OfficerChief Financial Officer
Nick Freeman Group Chief Financial Officer (CFO)
Roslyn Toms Group Executive - Legal and Chief Risk OfficerCompany Secretary
Edward Close Group Executive Australian Residents Health Insurance (GE ARHI)
Matt Paterson Group Executive Business Services (GE BS)
Roslyn Toms Group Executive Legal and Chief Risk Officer (GE LCRO)
Jordan French Senior Corporate CounselJoint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 71,381,922 15.63%
J P Morgan Nominees Australia Pty Limited 44,388,849 9.72%
Citicorp Nominees Pty Limited 26,995,166 5.91%
National Nominees Limited 13,839,661 3.03%
BNP Paribas Noms Pty Ltd 8,128,195 1.78%
Bnp Paribas Nominees Pty Ltd 4,964,819 1.09%
Citicorp Nominees Pty Limited i 3,770,904 0.83%
Mr Mark Anthony Fitzgibbon 1,438,864 0.31%
CPU Share Plans Pty Ltd 1,293,997 0.28%
Mrs Michelle McPherson 907,911 0.20%
HSBC Custody Nominees (Australia) Limited i 868,906 0.19%
HSBC Custody Nominees (Australia) Limited ii 782,146 0.17%
Powerwrap Limited 780,739 0.17%
HSBC Custody Nominees (Australia) Limited Gsco Eca 745,228 0.16%
Fitzy (NSW) Pty Ltd 724,621 0.16%
BNP Paribas Nominees Pty Ltd i 650,491 0.14%
AMP Life Limited 563,538 0.12%
UBS Nominees Pty Ltd 431,772 0.09%
Mr John Arthur Foyle Turner 430,000 0.09%
Australian Executor Trustees Limited 412,687 0.09%